Celcuity
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 55
- Market Cap
- -
- Introduction
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Conditions
- Breast Cancer
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 674
- Registration Number
- NCT06757634
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
- Conditions
- mCRPC (Metastatic Castration-resistant Prostate Cancer)Genital Diseases, MaleProstatic DiseaseProstatic Neoplasms, Castration-ResistantUrogenital Diseases, MaleProstate Cancer
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 54
- Registration Number
- NCT06190899
- Locations
- πͺπΈ
Institut Catala d'Oncologia, Barcelona, Spain
πͺπΈHospital Clinic Barcelona, Barcelona, Spain
πͺπΈHospital General Universitario Gregorio Maranon, Madrid, Spain
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 701
- Registration Number
- NCT05501886
- Locations
- πΊπΈ
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
πΊπΈBond & Steele Clinic, P.A. d/b/a Bond Clinic, P.A., Winter Haven, Florida, United States
πΊπΈJohn D. Archbold Memorial Hospital, Thomasville, Georgia, United States
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
- Conditions
- Breast Neoplasm Malignant Female
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Celcuity Inc
- Registration Number
- NCT05134922
- Locations
- πΊπΈ
University of Michigan, Ann Arbor, Michigan, United States
πΊπΈOhio State University Comprehensive Cancer Center, Columbus, Ohio, United States
πΊπΈThe University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 141
- Registration Number
- NCT02684032
- Locations
- πΊπΈ
The Emory Clinic, Atlanta, Georgia, United States
πΊπΈWinship Cancer Institute, Atlanta, Georgia, United States
πΊπΈKarmanos Cancer Institute, Farmington Hills, Michigan, United States